Skip to main content

Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new coronavirus

Project description

Testing new drug solnatide IMP in COVID-19 patients

Coronavirus disease 2019 (COVID-19) has turned into a pandemic with millions of infected individuals worldwide. Patients suffer from severe respiratory failure and a life-threatening pulmonary oedema (PPO) that leads to acute respiratory distress syndrome (ARDS) in 30 % of the cases. The EU-funded SOLNATIDE project aims to test the novel drug solnatide IMP in COVID-19 patients. Solnatide has already been tested in one Phase I and in two Phase II clinical studies for the treatment of ARDS. Given the lack of available drugs for treating patients infected with the new coronavirus, solnatide constitutes a promising solution for tackling the exacerbated pulmonary manifestations of the virus.

Call for proposal

H2020-SC1-PHE-CORONAVIRUS-2020
See other projects for this call

Coordinator

RTDS - VEREIN ZUR FORDERUNG DER KOMMUNIKATION UND VERMITTLUNG VON FORSCHUNG, TECHNOLOGIE UND INNOVATION (RTDS VEREIN, ENGL. RTDS ASSOCIATION)
Address
Lerchengasse 25/2-3
1080 Wien
Austria
Activity type
Other
EU contribution
€ 132 228,75

Participants (4)

OPIS SRL
Italy
EU contribution
€ 365 833,34
Address
Via Matteotti 10
20832 Palazzo Aliprandi
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 150 000
Address
Geschwister Scholl Platz 1
80539 Muenchen
Activity type
Higher or Secondary Education Establishments
BCN PEPTIDES SA
Spain
EU contribution
€ 310 937,50
Address
Carretera Comarcal C-244 Km 22 Poligon Industrial Els Fogars Sector Ii
08777 Santa Quinti De Mediona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH
Austria
EU contribution
€ 667 025,41
Address
Mariahilferstrasse 136 Top 1.15
1150 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)